BeyondSpring

Investigational small molecule with GEF‑H1–mediated dendritic cell activation; potential to enhance anti‑tumor responses across prioritized indications.

NSCLC Poster 2025

10.2022 American Society of Clinical Oncology (ASCO) Annual Meeting (2022) Subgroup Analysis of Non-Squamous EGFR Wild-Type (WT) 2nd/3rdLine NSCLC

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a

- Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy - Single agent plinabulin (day 1

Topline results, released in early August, demonstrated improvement in overall survival (OS) for the combination vs. docetaxel alone as well as

Study met the primary endpoint showing statistically significant improvement in overall survival (OS) for the combination (DP) vs. docetaxel (D). Study

BeyondSpring Pharmaceuticals is focused on developing innovative cancer therapies to improve clinical outcomes. We are developing treatments in China and the United States.

Enim vestibulum non pellentesque adipiscing tortor eget scelerisque at. Adipiscing purus ac rhoncus ut et facilisis quisque. Nibh volutpat dolor aliquet quis. Sed egestas neque dignissim nibh. Venenatis aliquam nam vitae consequat ut id accumsan mauris et. Posuere faucibus nam nibh facilisis dignissim facilisi malesuada fermentum neque. Proin faucibus varius leo donec turpis tempus suspendisse. […]

Welcome to the BeyondSpring Inc. (“BeyondSpring”) website. The information provided on this site is for general informational purposes only. Please read and review these Terms of Use carefully before accessing or using this website. By accessing or using this site, you acknowledge that you have read, understood and agreed to abide by the Terms of […]

BeyondSpring Pharmaceuticals is focused on developing innovative cancer therapies to improve clinical outcomes. We are developing treatments in China and the United States.